Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer

Cancer Medicine

Volumn 4, Issue 2, 2015, Pages 161-173

  Schuler, Kevin M ^a   Rambally, Brooke S ^b   Difurio, Megan J ^c   Sampey, Brante P ^d   Gehrig, Paola A ^e   Makowski, Liza ^e,f   Bae Jump, Victoria L ^e  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Pinehurst Pathology Center   (United States)

^d METABOLON INC   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f The University of North Carolina at Chapel Hill   (United States)

Author keywords

Endometrial cancer; Metabolomics; Metformin; mTOR pathway

Indexed keywords

ADENOSINE PHOSPHATE; ESTROGEN RECEPTOR; FATTY ACID; GLYCOGEN; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROGESTERONE RECEPTOR; PROTEIN KINASE; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; ENDOMETRIUM CANCER; FATTY ACID OXIDATION; FEMALE; GLYCOGEN METABOLISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOLYSIS; METABOLOMICS; MIDDLE AGED; PRIORITY JOURNAL; AGED; BLOOD; CELL PROLIFERATION; COMPLICATION; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; OBESITY; PATHOLOGY; PREOPERATIVE CARE; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METABOLOMICS; METFORMIN; MIDDLE AGED; OBESITY; PREOPERATIVE CARE; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84964694192     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.353     Document Type: Article

References (46)

1. Siegel, R., J. Ma, Z. Zou, and A. Jemal . 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64:9-29 doi: 10.3322/caac.21208.
2. Schmandt, R. E., D. A. Iglesias, N. N. Co, and K. H. Lu . 2011. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am. J. Obstet. Gynecol. 205:518-525 doi: 10.1016/j.ajog.2011.05.042.
3. Setiawan, V. W., H. P. Yang, M. C. Pike, S. E. McCann, H. Yu, Y. B. Xiang, et al. 2013. Type I and II endometrial cancers: have they different risk factors? J. Clin. Oncol. 31:2607-2618 doi: 10.1200/JCO.2012.48.2596.
4. Fader, A. N., L. N. Arriba, H. E. Frasure, and V. E. von Gruenigen . 2009. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol. Oncol. 114:121-127 doi: 10.1016/j.ygyno.2009.03.039.
5. Calle, E. E., C. Rodriguez, K. Walker-Thurmond, and M. J. Thun . 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348:1625-1638.
6. Johnson, A. R., J. J. Milner, and L. Makowski . 2012. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol. Rev. 249:218-238 doi: 10.1111/j.1600-065X.2012.01151.x.
7. Pollak, M. N. 2012. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2:778-790 doi: 10.1158/2159-8290.CD-12-0263..
8. Emami Riedmaier, A., P. Fisel, A. T. Nies, E. Schaeffeler, and M. Schwab . 2013. Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol. Sci. 34:126-135 doi: 10.1016/j.tips.2012.11.005.
9. Yin, M., J. Zhou, E. J. Gorak, and F. Quddus . 2013. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 18:1248-1255 doi: 10.1634/theoncologist.2013-0111.
10. Franciosi, M., G. Lucisano, E. Lapice, G. F. Strippoli, F. Pellegrini, and A. Nicolucci . 2013. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 8:e71583 doi: 10.1371/journal.pone.0071583.
11. Ko, E. M., P. Walter, A. Jackson, L. Clark, J. Franasiak, C. Bolac, et al. 2014. Metformin is associated with improved survival in endometrial cancer. Gynecol. Oncol. 132:438-442 doi: 10.1016/j.ygyno.2013.11.021.
12. Nevadunsky, N. S., A. Van Arsdale, H. D. Strickler, A. Moadel, G. Kaur, M. Frimer, et al. 2014. Metformin use and endometrial cancer survival. Gynecol. Oncol. 132:236-240 doi: 10.1016/j.ygyno.2013.10.026.
13. Currie, C. J., C. D. Poole, S. Jenkins-Jones, E. A. Gale, J. A. Johnson, and C. L. Morgan . 2012. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299-304 doi: 10.2337/dc11-1313.
14. Gehrig, P. A., and V. L. Bae-Jump . 2010. Promising novel therapies for the treatment of endometrial cancer. Gynecol. Oncol. 116:187-194 doi: 10.1016/j.ygyno.2009.10.041.
15. Dedes, K. J., D. Wetterskog, A. Ashworth, S. B. Kaye, and J. S. Reis-Filho . 2011. Emerging therapeutic targets in endometrial cancer. Nat. Rev. Clin. Oncol. 8:261-271 doi: 10.1038/nrclinonc.2010.216.
16. Cantrell, L. A., C. Zhou, A. Mendivil, K. M. Malloy, P. A. Gehrig, and V. L. Bae-Jump . 2010. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol. Oncol. 116:92-98.
17. Hanna, R. K., C. Zhou, K. M. Malloy, L. Sun, Y. Zhong, P. A. Gehrig, et al. 2012. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecol. Oncol. 125:458-469 doi: 10.1016/j.ygyno.2012.01.009.
18. Hadad, S., T. Iwamoto, L. Jordan, C. Purdie, S. Bray, L. Baker, et al. 2011. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat. 128:783-794 doi: 10.1007/s10549-011-1612-1.
19. Niraula, S., R. J. Dowling, M. Ennis, M. C. Chang, S. J. Done, N. Hood, et al. 2012. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res. Treat. 135:821-830 doi: 10.1007/s10549-012-2223-1.
20. Bonanni, B., M. Puntoni, M. Cazzaniga, G. Pruneri, D. Serrano, A. Guerrieri-Gonzaga, et al. 2012. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J. Clin. Oncol. 30:2593-2600 doi: 10.1200/JCO.2011.39.3769.
21. Lawton, K. A., A. Berger, M. Mitchell, K. E. Milgram, A. M. Evans, L. Guo, et al. 2008. Analysis of the adult human plasma metabolome. Pharmacogenomics 9:383-397 doi: 10.2217/14622416.9.4.383.
22. Reitman, Z. J., G. Jin, E. D. Karoly, I. Spasojevic, J. Yang, K. W. Kinzler, et al. 2011. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. USA 108:3270-3275 doi: 10.1073/pnas.1019393108.
23. Evans, A. M., C. D. DeHaven, T. Barrett, M. Mitchell, and E. Milgram . 2009. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal. Chem. 81:6656-6667 doi: 10.1021/ac901536 h.
24. Freemerman, A. J., A. R. Johnson, G. N. Sacks, J. J. Milner, E. L. Kirk, M. A. Troester, et al. 2014. Metabolic reprogramming of macrophages: glucose transporter (GLUT1)-mediated glucose metabolism drives a pro- inflammatory phenotype. J. Biol. Chem. 289:7884-7896 doi: 10.1074/jbc.M113.522037.
25. Breiman, L. 2001. Random forests. Machine Learn. 45:5-32. doi:10.1023/a:1010933404324.
26. Robert, F., S. Fendri, L. Hary, C. Lacroix, M. Andrejak, and J. D. Lalau . 2003. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab. 29:279-283.
27. Zhang, T., J. He, C. Xu, L. Zu, H. Jiang, S. Pu, et al. 2009. Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes. J. Mol. Endocrinol. 42:57-66 doi: 10.1677/JME-08-0130.
28. Flechtner-Mors, M., H. H. Ditschuneit, C. P. Jenkinson, A. Alt, and G. Adler . 1999. Metformin inhibits catecholamine-stimulated lipolysis in obese, hyperinsulinemic, hypertensive subjects in subcutaneous adipose tissue: an in situ microdialysis study. Diabet. Med. 16:1000-1006.
29. Ren, T., J. He, H. Jiang, L. Zu, S. Pu, X. Guo, et al. 2006. Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-alpha or isoproterenol. J. Mol. Endocrinol. 37:175-183 doi: 10.1677/jme.1.02061.
30. Abbasi, F., V. Kamath, A. A. Rizvi, M. Carantoni, Y. D. Chen, and G. M. Reaven . 1997. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue. Diabetes Care 20:1863-1869.
31. Grisouard, J., K. Timper, E. Bouillet, T. Radimerski, K. Dembinski, D. M. Frey, et al. 2011. Metformin counters both lipolytic/inflammatory agents-decreased hormone sensitive lipase phosphorylation at Ser-554 and -induced lipolysis in human adipocytes. Arch. Physiol. Biochem. 117:209-214 doi: 10.3109/13813455.2010.550925.
32. Geerling, J. J., M. R. Boon, G. C. van der Zon, S. A. van den Berg, A. M. van den Hoek, M. Lombes, et al. 2014. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. Diabetes 63:880-891 doi: 10.2337/db13-0194.
33. Otto, M., J. Breinholt, and N. Westergaard . 2003. Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes. Diabetes Obes. Metab. 5:189-194.
34. Ouyang, J., R. A. Parakhia, and R. S. Ochs . 2011. Metformin activates AMP kinase through inhibition of AMP deaminase. J. Biol. Chem. 286:1-11 doi: 10.1074/jbc.M110.121806.
35. Owen, M. R., E. Doran, and A. P. Halestrap . 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348(Pt 3):607-614.
36. Holmes, B. F., E. J. Kurth-Kraczek, and W. W. Winder . 1985. Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J. Appl. Physiol. 1999:1990-1995.
37. Fu, J., J. Yuan, N. Zhang, B. Gao, G. Fu, Y. Tu, et al. 2012. Anti-diabetic activities of acanthopanax senticosus polysaccharide (ASP) in combination with metformin. Int. J. Biol. Macromol. 50:619-623 doi: 10.1016/j.ijbiomac.2012.01.034.
38. Algire, C., M. Zakikhani, M. J. Blouin, J. H. Shuai, and M. Pollak . 2008. Metformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growth. Endocr. Relat. Cancer 15:833-839.
39. Phoenix, K. N., F. Vumbaca, M. M. Fox, R. Evans, and K. P. Claffey . 2009. Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res. Treat. 123:333-344.
40. Soliman, P., R. Broaddus, S. N. Westin, D. A. Iglesias, J. K. Burzawa, Q Zhang, et al. 2014. Prospective evaluation of the molecular effects of metformin in the endometrim in women with newly diagnosed endometrial cancer: a window of opportunity study. Presented at the 2014 Annual Meeting of the American Society of Clinical Oncology.
41. Mitsuhashi, A., T. Kiyokawa, Y. Sato, and M. Shozu . 2014. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial. Cancer. doi: 10.1002/cncr.28853. [Epub ahead of print].
42. Pierotti, M. A., F. Berrino, M. Gariboldi, C. Melani, A. Mogavero, T. Negri, et al. 2012. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 32:1475-1487. doi: 10.1038/onc.2012.181.
43. Zhang, Q., J. Celestino, R. Schmandt, A. S. McCampbell, D. L. Urbauer, L. A. Meyer, et al. 2013. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. Am. J. Obstet. Gynecol. 209:e1-e12 doi: 10.1016/j.ajog.2013.03.008.
44. Xie, Y., Y. L. Wang, L. Yu, Q. Hu, L. Ji, Y. Zhang, et al. 2011. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J. Steroid Biochem. Mol. Biol. 126:113-120 doi: 10.1016/j.jsbmb.2010.12.006.
45. Giles, E. D., E. A. Wellberg, D. P. Astling, S. M. Anderson, A. D. Thor, S. Jindal, et al. 2012. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res. 72:6490-6501 doi: 10.1158/0008-5472.CAN-12-1653.
46. Markowska, A., M. Pawalowska, V. Filas, K. Korski, M. Grybos, S. Sajdak, et al. 2013. Does metformin affect ER, PR, IGF-1R, beta-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer? Diabetol. Metab. Syndr. 5:76 doi: 10.1186/1758-5996-5-76.